{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Open+Label+Extension+Study&page=53",
    "query": {
      "intervention": "Open Label Extension Study",
      "page": 53
    },
    "page_size": 10
  },
  "pagination": {
    "page": 53,
    "page_size": 10,
    "total_count": 2084,
    "total_pages": 209,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Open+Label+Extension+Study&page=54&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Open+Label+Extension+Study&page=52&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-05T15:49:07.250Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02970669",
      "title": "Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Heart Failure, Reduced Ejection Fraction"
      ],
      "interventions": [
        {
          "name": "sacubitril/valsartan (LCZ696)",
          "type": "DRUG"
        },
        {
          "name": "enalapril",
          "type": "DRUG"
        },
        {
          "name": "matching placebo sacubitril/valsartan (LCZ696)",
          "type": "DRUG"
        },
        {
          "name": "matching placebo enalapril",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 140,
      "start_date": "2016-12-16",
      "completion_date": "2018-03-19",
      "has_results": true,
      "last_update_posted_date": "2021-10-07",
      "last_synced_at": "2026-11-05T15:49:07.250Z",
      "location_count": 23,
      "location_summary": "Fort Payne, Alabama • Beverly Hills, California • Stockton, California + 20 more",
      "locations": [
        {
          "city": "Fort Payne",
          "state": "Alabama"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Stockton",
          "state": "California"
        },
        {
          "city": "West Hills",
          "state": "California"
        },
        {
          "city": "Doral",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02970669"
    },
    {
      "nct_id": "NCT06101823",
      "title": "Phase 2a Study of Efficacy and Safety of OpSCF in Moderate to Severe AD (Atopic Dermatitis)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Atopic Dermatitis"
      ],
      "interventions": [
        {
          "name": "OpSCF",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Insmed Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 50,
      "start_date": "2023-11-21",
      "completion_date": "2025-08-18",
      "has_results": true,
      "last_update_posted_date": "2026-09-11",
      "last_synced_at": "2026-11-05T15:49:07.250Z",
      "location_count": 18,
      "location_summary": "Birmingham, Alabama • Fountain Valley, California • Inglewood, California + 15 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Inglewood",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Sherman Oaks",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06101823"
    },
    {
      "nct_id": "NCT03989947",
      "title": "An Extension Study to Evaluate Safety and Efficacy of BMN 111 in Children With Achondroplasia",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Achondroplasia"
      ],
      "interventions": [
        {
          "name": "Active BMN 111: Subcutaneous injection of recommended dose of BMN 111 based on weight-band dosing once daily.",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "BioMarin Pharmaceutical",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "15 Months",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "15 Months and older"
      },
      "enrollment_count": 73,
      "start_date": "2019-06-12",
      "completion_date": "2038-05",
      "has_results": false,
      "last_update_posted_date": "2026-03-13",
      "last_synced_at": "2026-11-05T15:49:07.250Z",
      "location_count": 9,
      "location_summary": "Oakland, California • Torrance, California • Wilmington, Delaware + 6 more",
      "locations": [
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Wilmington",
          "state": "Delaware"
        },
        {
          "city": "Decatur",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03989947"
    },
    {
      "nct_id": "NCT04225871",
      "title": "Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Generalized Myasthenia Gravis"
      ],
      "interventions": [
        {
          "name": "zilucoplan (RA101495)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "UCB Biopharma SRL",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 200,
      "start_date": "2019-12-23",
      "completion_date": "2026-07-31",
      "has_results": false,
      "last_update_posted_date": "2026-10-16",
      "last_synced_at": "2026-11-05T15:49:07.250Z",
      "location_count": 33,
      "location_summary": "Mobile, Alabama • Phoenix, Arizona • Irvine, California + 29 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Pasadena",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04225871"
    },
    {
      "nct_id": "NCT07723963",
      "title": "A Study to Evaluate the Safety and Efficacy of JZP926 Capsule for the Treatment of Juvenile Myoclonic Epilepsy",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Juvenile Myoclonic Epilepsy"
      ],
      "interventions": [
        {
          "name": "JZP926 capsule",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Jazz Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "10 Years and older"
      },
      "enrollment_count": 260,
      "start_date": "2026-09-18",
      "completion_date": "2028-08-01",
      "has_results": false,
      "last_update_posted_date": "2026-11-02",
      "last_synced_at": "2026-11-05T15:49:07.250Z",
      "location_count": 23,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • Sacramento, California + 20 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07723963"
    },
    {
      "nct_id": "NCT06807281",
      "title": "A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Atopic Dermatitis"
      ],
      "interventions": [
        {
          "name": "Abrocitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "11 Years",
        "sex": "ALL",
        "summary": "2 Years to 11 Years"
      },
      "enrollment_count": 450,
      "start_date": "2025-12-02",
      "completion_date": "2032-02-22",
      "has_results": false,
      "last_update_posted_date": "2026-11-05",
      "last_synced_at": "2026-11-05T15:49:07.250Z",
      "location_count": 11,
      "location_summary": "Birmingham, Alabama • North Little Rock, Arkansas • San Diego, California + 7 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "North Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06807281"
    },
    {
      "nct_id": "NCT03395184",
      "title": "Study To Evaluate The Efficacy And Safety Of Oral PF-06651600 And PF-06700841 In Subjects With Moderate To Severe Crohn's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Crohn's Disease"
      ],
      "interventions": [
        {
          "name": "PF-06651600 Placebo",
          "type": "DRUG"
        },
        {
          "name": "PF-06651600",
          "type": "DRUG"
        },
        {
          "name": "Placebo PF-06700841",
          "type": "DRUG"
        },
        {
          "name": "PF-06700841",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 244,
      "start_date": "2018-02-02",
      "completion_date": "2023-10-19",
      "has_results": true,
      "last_update_posted_date": "2024-10-30",
      "last_synced_at": "2026-11-05T15:49:07.250Z",
      "location_count": 57,
      "location_summary": "Dothan, Alabama • Beverly Hills, California • Los Angeles, California + 25 more",
      "locations": [
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03395184"
    },
    {
      "nct_id": "NCT03110575",
      "title": "12-Week Open-Label Extension Study of TNX-102 SL in PTSD Patients",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "PTSD"
      ],
      "interventions": [
        {
          "name": "TNX-102 SL",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tonix Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 190,
      "start_date": "2017-06-20",
      "completion_date": "2018-07-27",
      "has_results": true,
      "last_update_posted_date": "2025-02-06",
      "last_synced_at": "2026-11-05T15:49:07.250Z",
      "location_count": 32,
      "location_summary": "Phoenix, Arizona • Rogers, Arkansas • Beverly Hills, California + 28 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Rogers",
          "state": "Arkansas"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03110575"
    },
    {
      "nct_id": "NCT00401726",
      "title": "Open-Label, Randomized Study Evaluating Treatment With Venlafaxine Extended-Release Plus Dialogues Time to Talk Program",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Depressive Disorder, Major"
      ],
      "interventions": [
        {
          "name": "Venlafaxine ER",
          "type": "DRUG"
        },
        {
          "name": "Dialogues Time to Talk Program",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BEHAVIORAL"
      ],
      "sponsor": "Wyeth is now a wholly owned subsidiary of Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 537,
      "start_date": "2006-06",
      "completion_date": "2007-10",
      "has_results": true,
      "last_update_posted_date": "2012-04-23",
      "last_synced_at": "2026-11-05T15:49:07.250Z",
      "location_count": 44,
      "location_summary": "Birmingham, Alabama • Mesa, Arizona • Little Rock, Arkansas + 39 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "San Jose",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00401726"
    },
    {
      "nct_id": "NCT07003425",
      "title": "A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Atopic Dermatitis"
      ],
      "interventions": [
        {
          "name": "APG777",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Apogee Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 350,
      "start_date": "2025-05-14",
      "completion_date": "2029-12",
      "has_results": false,
      "last_update_posted_date": "2026-11-03",
      "last_synced_at": "2026-11-05T15:49:07.250Z",
      "location_count": 23,
      "location_summary": "Fountain Valley, California • Los Angeles, California • Coral Gables, Florida + 20 more",
      "locations": [
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Coral Gables",
          "state": "Florida"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Margate",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07003425"
    }
  ]
}